8:31 AM ET
8-K
Business Update
Mira Pharmaceuticals Business Update
MIRA Pharmaceuticals has advanced its Ketamir-2 Phase 2a clinical program for chemotherapy-induced peripheral neuropathy (CIPN) toward site initiation following a protocol review by the FDA. The company has incorporated the regulator's feedback and submitted the protocol for Institutional Review Board (IRB) review, with site initiation targeted for the first quarter of 2027.
- Counterparty
- FDA